Kwality PharmaceuticalsBOM:539997 -3.48%64 EBITDA Margin % is 25.34% as of Mar. 2026, which is 62% above its 10-year median of 15.68. GuruFocus rates BOM:539997 with a GF Score™ of 64/100 and a GF Value™ of ₹1,155.94 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 953 Drug Manufacturers companies, Kwality Pharmaceuticals ranks better than 76.81% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kwality Pharmaceuticals EBITDA Margin % Related Terms
Kwality Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539997 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kwality Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kwality Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kwality Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kwality Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kwality Pharmaceuticals (BOM:539997) has a EBITDA Margin % of 25.34% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kwality Pharmaceuticals and its competitors. This is 62% above median its historical median of 15.68. Over the past decade, Kwality Pharmaceuticals' EBITDA Margin % has ranged from 9.09 to 38.40. According to the industry distribution chart, Kwality Pharmaceuticals ranks #221 out of 953 companies in the Drug Manufacturers industry, placing it in the top 23.2%.
Is Kwality Pharmaceuticals' EBITDA Margin % too high?
Kwality Pharmaceuticals' current EBITDA Margin % of 25.34% is 62% above median its 10-year median of 15.68. Over the past 10 years, this metric has ranged from a low of 9.09 to a high of 38.40. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Kwality Pharmaceuticals' value of 25.34% is 102.1% above this industry median. Based on the distribution chart, Kwality Pharmaceuticals ranks #221 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kwality Pharmaceuticals has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kwality Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kwality Pharmaceuticals ranks #221 out of 953 companies for EBITDA Margin %. This places Kwality Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. Kwality Pharmaceuticals' value of 25.34% is 102.1% above this benchmark. Historically, Kwality Pharmaceuticals' own EBITDA Margin % has ranged from 9.09 to 38.40 over the past decade. While the company's 10-year median is 15.68 vs. the industry median of 12.54, Kwality Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kwality Pharmaceuticals's current EBITDA Margin % of 25.34% is 102.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kwality Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kwality Pharmaceuticals's current EBITDA Margin % is 25.34%, which is 62% above median its own 10-year median of 15.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kwality Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Kwality Pharmaceuticals (BOM:539997) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,155.94, compared to a current price of ₹2,704.70 — trading 134% above its estimated fair value. The current EBITDA Margin % is 25.34%, which is 62% above median its 10-year median of 15.68 and 102.1% above the Drug Manufacturers industry median of 12.54. Kwality Pharmaceuticals' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kwality Pharmaceuticals (BOM:539997), the current EBITDA Margin % is 25.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kwality Pharmaceuticals (BOM:539997) Overvalued in 2026?
Based on GuruFocus' analysis, Kwality Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,704.70 is trading 134% above its estimated GF Value™ of ₹1,155.94.
GuruFocus considers Kwality Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:539997:
EBITDA Margin %: 25.34% (62% above median its 10-year median of 15.68)
GF Value™: ₹1,155.94 vs. price of ₹2,704.70 (134% above fair value)
Industry Position: 102.1% above the Drug Manufacturers median (#221 of 953)
No single metric tells the full story. See the BOM:539997 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kwality Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing finished pharmaceutical formulations in a dosage form. The company manufactures and exports pharmaceutical formulations in liquid orals, dry syrups, tablets, capsules, sterile powder for injections, and small-volume injectables.
64GF Score
Get the complete analysis for BOM:539997
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539997 has been successfully added to your 
